Abbreviations {#nomen0010}
=============

SLE

:   Systemic Lupus Erythematosus

*M. pneumoniae*

:   *Mycoplasma pneumoniae*

MP

:   *Mycoplasma pneumoniea* pneumonia

CT scan

:   computed tomography scan

ANA

:   Antinuclear antibody

1. Introduction {#sec1}
===============

Although *Mycoplasma pneumoniae* (*M.pneumoniae*) infections are typically mild and self-limiting, this organism is one of the most common causes of atypical pneumonia, accounting for up to 35% of cases in the United States. *M. pneumoniae* is transmitted from person to person by infected respiratory droplets during close contact. The incubation period after exposure averages 2to 3weeks [@bib1]. Infections with *M. pneumoniae* are referred to as walking pneumonia.

Although pleural effusion is rare in cases of *Mycoplasma pneumoniae* pneumonia (MP), two distinct types of pleural effusion in affected patients have been reported, one of which is benign and mostly reactive, and the second of which contains *Mycoplasma* DNA and is a more protracted disease [@bib2].

Systemic lupus erythematosus (SLE) is a chronic, multisystem disorder. SLE patients can experience flares ranging from mild to severe. Mild flares are associated with low-grade fever and arthralgia, where as moderate flares are associated with chest pain, swelling of the wrists, and right pleural effusion. Severe flares are associated with new-onset renal failure secondary to lupus nephritis [@bib3].

Patients with SLE are at increase risk of developing infections. The increased frequency of infection with *Mycoplasma* species among patients with SLE was first suggested to be secondary to environmental factors and it is postulated that in SLE, *mycoplasma* peptides may provoke the production of autoreactive clones [@bib4]. Infections of *mycoplasma* have been reported in SLE patients. In 1971, Jansson et al. isolated *Mycoplasma* from the bone marrow of 3 SLE patients [@bib5].

2. Case presentation {#sec2}
====================

A 26-year-old male with no past medical history who works as a chef at a restaurant presented to our hospital for evaluation of fever, productive cough, and shortness of breath with progressively worsening right-sided chest pain of about 5-days duration. He denied experiencing hemoptysis, hematemesis, arthralgia, diarrhea, nausea, vomiting, or abdominal pain. He had no exposure to birds, recent travel, or sick contacts. He also denied use of recreational drugs and alcohol and indicated that he is a non-smoker.

On physical examination, the patient was of thin build, in mild respiratory distress, febrile with a temperature of 101.5°F, heart rate 94 per minute, blood pressure of 146/84 mm Hg, respiratory rate of 18 per minute, and oxygen saturation of 94% on 2 liters of oxygen via a nasal cannula. On the right side of the chest, bronchial breathing sounds were noted. On cardiovascular examination, heart sounds were normal. The abdomen was soft upon palpation, with no organomegaly noted. Neurologic examination was unremarkable.

Laboratory analysis was relevant for leukocytosis (16.5 × 10^3^ cells/μl) and mild anemia, with hemoglobin and hematocrit values of 9.7 g/dl and 29%, respectively. A creatinine level of 3.4 mg/dl was also noted. Liver function tests were within normal limits. Urinalysis showed proteinuria, considerable blood, and the test was positive for casts. Serum and urine toxicology were negative.

Chest X-ray showed bilateral pleural effusion (more pronounced on the right than left) and right lower-lobe infiltrate ([Fig. 1](#fig1){ref-type="fig"}A).Fig. 1A: Chest X-ray on day 1 showing bilateral pleural effusion. Fig 1B: Chest X-ray on day 30 showing complete resolution of pleural effusion.Fig. 1

Bedside ultrasound revealed loculated pleural effusion ([Fig. 2](#fig2){ref-type="fig"}A).Fig. 2: A: Ultrasound image showing loculated pleural effusion. Fig 2B: Yellow, turbid, pleural fluid.Fig. 2

A subsequent chest computed tomography (CT) scan confirmed loculated pleural effusion ([Fig. 3](#fig3){ref-type="fig"}A).Fig. 3A: CT scan of the chest on day 1 showing loculated pleural effusion. Fig 3B: CT scan of the chest on day 7 showing improvement in loculated effusion after intrapleural fibrinolytic therapy. Fig 3C: CT scan of the chest on day 30 showing complete resolution of pleural effusion.Fig. 3

Bedside ultrasound-guided thoracentesis was carried out, and a pleural catheter was placed ([Fig. 2](#fig2){ref-type="fig"}B).

Pleural fluid was drained from three different loculation sites under ultrasound guidance. The results of the pleural fluid analysis are shown in [Table 1](#tbl1){ref-type="table"}.Table 1Pleural fluid analysis.Table 1ColorYellow, hazyYellow, cloudyYellowpH7.47.17.2WBC count (cells/mm^3^)35402800248Neutrophils95%96%70%Lymphocytes1%3%30%LDH (U/l)4522189565Protein (g/dl)3.54.33.6Albumin (g/dl)1.31.61.2Glucose75256Adenosine deaminase (U/l)18.4

The patient was started on antibiotics (vancomycin, piperacillin, and tazobactam) based on a presumptive diagnosis of pneumonia. His serum *Mycoplasma* IgM was 962 U/ml; cold hemagglutinin titer was 1:320; and levofloxacin was started and above antibiotics were deescalated. Analysis of pleural fluid revealed complicated parapneumonic pleural effusion. The patient then received anti-fibrinolytic therapy in the form of dornase alfa and tissue plasminogen activator for 3 days via pleural catheter. All cultures, including pleural fluid cultures, were negative. Repeat CT scan of the chest showed decreased pleural fluid and loculi ([Fig. 3](#fig3){ref-type="fig"}B).

Results of the patient\'s autoimmune work-up ([Table 2](#tbl2){ref-type="table"}) revealed the presence of SLE with lupus flare. The analyses revealed elevated ANA titer and homogenous speckled ANA pattern with anti-Ribonucleoprotein and anti-Smith positivity, indicative of lupus flare. The patient was therefore started on prednisone and hydroxychloroquine.Table 2Results of autoimmune work-up.Table 2Autoimmune work-upParameterResultANAPositiveANA titer1:640ANA patternHomogenousANA pattern 2SpeckledAnti-RNPPositive (4.3)Anti-SMPositive (6.4)Anti-DNA Ab\>300 IU/mlESR138Serum C3 complement (mg/dl)78 (ref 90--500mg/dl)Serum C4 complement (mg/dl)19 (ref 16--47mg/dl)Rheumatoid factor (IU/ml)\<14SSA/SSB\<1Anti-CCP\<20C-reactive protein148 mg/LCardiolipin antibodies IgA, IgM, IgGNegative

In subsequent evaluation of renal insufficiency, the patient underwent renal biopsy, which showed lupus nephritis ([Fig. 4](#fig4){ref-type="fig"}).Fig. 4(A) Light microscopy showing endocapillary proliferation with widespread 'wire loop' appearance in the glomerular capillary wall. (B)Histologic examination of tubular changes showing evidence of acute tubular necrosis and edema. (C) Light microscopy showing active crescent. (D) Immunofluorescence micrograph showing diffuse and globally distributed granular IgG deposits in the glomerular capillary walls.Fig. 4

He was then started on mycophenolate.

Prolonged hospital stay for almost three weeks inpatient, he was discharged home. Repeat chest X-ray ([Fig. 1](#fig1){ref-type="fig"}B).

CT scan of the chest ([Fig. 3](#fig3){ref-type="fig"}C) at the 1-month follow-up in the pulmonary clinic showed complete resolution of the loculated pleural effusion.

The patient continues to be followed in the pulmonary and rheumatology clinics.

Our case is unique, in that the patient had complicated parapneumonic effusion that responded well to anti-fibrinolytic therapy and antibiotics. He was newly diagnosed with SLE with concomitant MP leading to lupus flare with lupus nephritis.

3. Discussion {#sec3}
=============

*M. pneumoniae* accounts to the most common causes of lower respiratory tract infections in the community setting [@bib6]. The most common risk factors associated with *M. pneumoniae* include older adults, younger children, patients having immunocompromising conditions like HIV or on chemotherapy or on steroids, or smokers with lung disease [@bib7]. Our patient did not have any of the above risk factors for development of MP.

*M. pneumoniae* infection can present with a variety of symptoms, including cough, sore throat, vomiting, diarrhea, ear pain, articular pain, and myalgia. Extra-pulmonary abnormalities seen in *Mycoplasma* infection include hemolysis, rashes, polyarthralgia, myalgia, bullous myringitis, encephalitis, meningitis, hepatitis, myocarditis and glomerulonephritis [@bib8], [@bib9].

Rare complications associated with *M. pneumoniae* infection includes acute respiratory distress syndrome, hemophagocytic syndrome, Stevens-Johnson syndrome and disseminated intravascular coagulation [@bib10], [@bib11]. Pleural effusion associated with MP is rare. Shuvy et al. reported a case of empyema associated with *M. pneumoniae* [@bib12]. Kashif et al. reported a rare case of cavitary lesion of lung caused by Mycoplasma pneumonia [@bib13].

SLE is a rare, multi-organ autoimmune disorder. Arthralgia is a common symptom of both lupus and *Mycoplasma* infection. Various *Mycoplasma* species have been isolated from the joint fluid and synovial membrane of SLE patients [@bib14]. Pleural effusions in lupus are generally small, bilateral, and exudative, with elevated lactate dehydrogenase levels. Glucose levels are significantly lower in pleural fluid than in serum. Pleural fluid ANA are nonspecific, as they can also be elevated in malignancy. Pleural fluid ANA are rarely either massive or loculated. Serositis is common, and the cause of pleural effusion in SLE is usually cardiac, pulmonary embolism, or renal [@bib15].

Pulmonary complications of SLE include pleural disease, acute pneumonitis, diffuse alveolar hemorrhage, interstitial lung disease, pulmonary hypertension, thromboembolic disease, shrinking lung syndrome, and increased risk of lung infections [@bib16], [@bib17]. The most common pulmonary manifestation of SLE is pleurisy caused by the deposition of immune complexes in the blood vessels of the lungs, with subsequent complement activation and direct binding of anti-dsDNA antibodies to the mesothelium [@bib18]. Tissue damage in lupus is primarily via complement activation, subsequently leading to hypo-complementenemia. Class IV lupus nephritis is the most common severe form of lupus nephritis. Crescent formation, necrotizing lesions, and proliferative lesions can all be present in patients with active disease. Lesions affecting 50% or more of glomeruli have been observed under light microscopy [@bib19].

Test results indicative of lupus flare include increased serum anti-dsDNA antibody titers, hypo-complementenemia (C3, C4, and CH50), and elevated IgG levels. Clinical features associated with lupus flare are age \<25 years and renal, neurologic, and vasculitic involvement [@bib20]. Loculated effusion is rare in MP. If pleural effusions associated with lupus are small, no treatment is required. In larger but still mild effusions, non-steroidal anti-inflammatory drugs can be used; with large effusions, drainage and steroid therapy might be required.

Parapneumonic effusion in *Mycoplasma pneumoniae* pneumonia is one of the uncommon presentations, which occurs in 4--20% cases.

A Study done by Cha SI et al.; showed pleural fluid in *Mycoplasma pneumonia*e pneumonia was exudative lymphocytic predominant in five patients and one patient had polymorphonuclear leukocyte predominance.

On the contrary, they observed elevated ADA levels in five patients, but our patient\'s ADA level was low, acid fast bacilli stains were negative and the neutrophilic exudate culture was negative for bacterial or viral organisms [@bib21]. Retrospective analysis done by Linz DH et al.; showed five patients had pleural effusion which were moderate to large size, two patients had diagnostic thoracentesis which showed exudate with neutrophilic predominant effusion [@bib22].

Retrospective study done by Kim CH et al.; showed ratio of serum LDH to pleural fluid adenosine deaminase more then 7.5 favors MP related paraneumonic effusion. Our patient serum LDH was 254 and pleural fluid adenosine deaminase level was 18, so the ratio is 14, favoring MP related parapneumonic effusion [@bib23].

Our patient had loculated complicated parapneumonic effusion, which responded well to intrapleural fibrinolytic therapy. A study reported by Rahman et al. showed that fluid drainage is better with intrapleural t-PA-DNase therapy, resulting in decreased rates of surgical intervention and length of hospital stay [@bib24]. The main stay of therapy for possible *M. pneumoniae* infection include macrolides, doxycycline, or a fluoroquinolone [@bib25]. Our patient responded well to levofloxacin.

The goals of therapy for SLE patients are to prevent organ damage, minimize drug toxicity, and improve quality of life. Non-steroidal anti-inflammatory drugs and antimalarial drugs are used to treat mild symptoms of lupus. Oral corticosteroids and cytotoxic agents can be used in severe disease. Other immunosuppressive agents that can be used include cyclophosphamide, mycophenolate, and rituximab [@bib26].

Our patient was started on Levofloxacin and underwent intrapleural fibrinolytic therapy with t-PA and dornase alfa for loculated pleural effusion. Due to renal insufficiency, a kidney biopsy was performed, which showed stage IV lupus nephritis. The patient was initially started on prednisone and hydroxychloroquine; when a renal biopsy confirmed lupus nephritis, he was started on mycophenolate, which resulted in improved renal function.

4. Conclusion {#sec4}
=============

MP associated with complicated parapneumonic pleural effusion are rare. Diagnosis of lupus flare in patients with MP can prevent organ damage. Early diagnosis and timely intervention can lead to complete resolution.
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